- GlobeNewswire•23 minutes ago
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for niraparib ...
- GlobeNewswire•25 minutes ago
WALTHAM, Mass., Oct. 27, 2016-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application for niraparib has been submitted to and accepted ...
- Investor's Business Daily•yesterday
Tesaro has a commercial advantage over AstraZeneca in their competing ovarian cancer drugs, says RBC.
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||116.25 x 500|
|Ask||121.70 x 1000|
|Day's Range||117.30 - 120.95|
|52wk Range||29.51 - 122.98|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-16.91|
|Avg Vol (3m)||1,129,286|
|Dividend & Yield||N/A (N/A)|